Article count:10804 Read by:13623255

Account Entry

The world's first digital drug with drug implant chip approved in the US

Latest update time:2021-08-30 22:00
    Reads:

The U.S. Food and Drug Administration (FDA) approved the first digital drug in the United States on the 13th. This mental illness drug equipped with a sensor tracking system will send a signal to a smartphone after entering the human digestive system so that doctors can track the patient's medication status.


The drug, Abilify Mysite, is manufactured by Japan's Otsuka Pharmaceutical Co. It has a microchip implanted inside it. When a patient takes the drug, the chip mixes with stomach acid and sends a signal to a patch they wear. The patch records how much medication the patient takes and when, and transmits that information to a smartphone app for monitoring by the patient and doctor. The chip eventually passes through the digestive tract normally.


Aripiprazole is widely used to treat mental illnesses such as schizophrenia and manic depression. The FDA first approved aripiprazole for the treatment of schizophrenia in 2002. Otsuka Pharmaceutical has been working with a Silicon Valley company called Proteus Digital Health to test the drug for many years. The latter is responsible for providing drug chip technology.


This invention that can track patients' medication intake is mainly aimed at patients with mental illness, who often take their medication irregularly due to forgetfulness and other reasons, which affects treatment. Dr. Mitchell Mathis, director of the Psychiatry Products Division in the FDA's Center for Drug Evaluation and Research, said that the FDA supports the development and use of new technologies for prescription drugs, and being able to track the intake of psychiatric medications is useful for some patients.


The FDA also warned that the drug is not suitable for "real-time" or emergency tracking of drug intake because of potential detection delays or failures. The FDA also emphasized that the drug is not approved for the treatment of mental disorders related to dementia, and its safety and effectiveness in pediatric patients have not been proven.

The "Microbit Getting Started Guide" written by EEWORLD forum moderator: dcexpert is finally on the market!

To thank you for your support, from now until November 30 Click to read the original text Participants will have a chance to win a copy of the "Microbit Getting Started Guide" signed by DCExpert.


Long press the QR code below Add WeChat ID helloeeworld as a friend, indicate EEWORLD forum account + occupation and area of ​​interest , and you will be added to WeChat communication groups established in different fields after being reviewed and approved.


Featured Posts


Latest articlesabout

 
EEWorld WeChat Subscription

 
EEWorld WeChat Service Number

 
AutoDevelopers

About Us About Us Service Contact us Device Index Site Map Latest Updates Mobile Version

Site Related: TI Training

Room 1530, Zhongguancun MOOC Times Building,Block B, 18 Zhongguancun Street, Haidian District,Beijing, China Tel:(010)82350740 Postcode:100190

EEWORLD all rights reserved 京B2-20211791 京ICP备10001474号-1 电信业务审批[2006]字第258号函 京公网安备 11010802033920号 Copyright © 2005-2021 EEWORLD.com.cn, Inc. All rights reserved